

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

American Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/ajem

Assessment of the SpO₂/FiO₂ ratio as a tool for hypoxemia screening in the emergency department



Pierre Catoire, MD^{a,*}, Eric Tellier, MD, PhD^{a,b}, Caroline de la Rivière, MD^a, Marie-Christine Beauvieux, MD, PhD^{c,d}, Guillaume Valdenaire, MD^e, Michel Galinski, MD, PhD^{a,b}, Philippe Revel, MD^{a,b}, Xavier Combes, MD, PhD^{a,b}, Cédric Gil-Jardiné, MD, PhD^{a,b}

^a Emergency Medicine Department, University Hospital of Bordeaux, 1 place Amélie Raba Léon, Bordeaux 33000, France

^b INSERM, ISPED, Bordeaux Population Health research center INSERM U1219-"Injury Epidemiology Transport Occupation" team, Université de Bordeaux, 146 Rue Léo Saignat, Bordeaux 33000, France

^c University Hospital of Bordeaux, Biochemistry Department, Université de Bordeaux, 146 Rue Léo Saignat, Bordeaux 33000, France

^d Center for Magnetic Resonance of Biological Systems, UMR5536, Université de Bordeaux, 146 Rue Léo Saignat, Bordeaux 33000, France

e Clinique Mutualiste, Emergency Medicine Department, 46 Avenue du Dr Albert Schweitzer, Pessac 33600, France

ARTICLE INFO

Article history: Received 7 December 2020 Received in revised form 28 January 2021 Accepted 31 January 2021

Keywords: Respiratory insufficiency Oximetry COVID-19 Triage ROC curve

ABSTRACT

Objective: We assessed the performance of the ratio of peripheral arterial oxygen saturation to the inspired fraction of oxygen (SpO₂/FiO₂) to predict the ratio of partial pressure arterial oxygen to the fraction of inspired oxygen (PaO₂/FiO₂) among patients admitted to our emergency department (ED) during the SARS-CoV-2 outbreak. *Methods:* We retrospectively studied patients admitted to an academic-level ED in France who were undergoing a joint measurement of SpO₂ and arterial blood gas. We compared SpO₂ with SaO₂ and evaluated performance of the SpO₂/FiO₂ ratio for the prediction of 300 and 400 mmHg PaO₂/FiO₂ cut-off values in COVID-19 positive and negative subgroups using receiver-operating characteristic (ROC) curves.

Results: During the study period from February to April 2020, a total of 430 arterial samples were analyzed and collected from 395 patients. The area under the ROC curves of the SpO_2/FiO_2 ratio was 0.918 (Cl 95% 0.885–0.950) and 0.901 (Cl 95% 0.872–0.930) for PaO_2/FiO_2 thresholds of 300 and 400 mmHg, respectively. The positive predictive value (PPV) of an SpO_2/FiO_2 threshold of 350 for PaO_2/FiO_2 inferior to 300 mmHg was 0.88 (Cl95% 0.84–0.91), whereas the negative predictive value (NPV) of the SpO_2/FiO_2 threshold of 470 for PaO_2/FiO_2 inferior to 400 mmHg was 0.89 (Cl95% 0.75–0.96). No significant differences were found between the subgroups.

Conclusions: The SpO₂/FiO₂ ratio may be a reliable tool for hypoxemia screening among patients admitted to the ED, particularly during the SARS-CoV-2 outbreak.

© 2021 Published by Elsevier Inc.

1. Introduction

1.1. Background

Acute respiratory distress is a common reason for emergency department (ED) admission. Since the end of 2019, healthcare workers have been facing the coronavirus disease (COVID-19) pandemic due to SARS-CoV-2, with a major risk of overcrowding in the ED. Severe COVID-19 infections are associated with hypoxemia, the severity of which can quickly become life-threatening.

The development of tools for the initial assessment of the degree of hypoxemia among patients with respiratory symptoms is essential.

E-mail address: pierre.catoire@chu-bordeaux.fr (P. Catoire).

Such a tool should reduce both under-triage, allowing critical patients to quickly receive the appropriate level of care, and over-triage, maintaining critical care capacity despite an influx of patients. An appropriate triage tool should also be applicable for all causes of respiratory distress, whether related to COVID-19 or not. Limited reliable data are available for the triage of hypoxemic patients in the ED, yet it could be particularly useful during the COVID-19 pandemic.

1.2. Importance

Early diagnosis of critical hypoxemia is important for both COVID-19 infection and Acute Respiratory Distress Syndrome (ARDS) based on the ratio of partial pressure arterial oxygen to the fraction of inspired oxygen (PaO_2/FiO_2) [1,2]. This indicator has been validated in many pathological situations [3,4] but requires an arterial blood sample and therefore is often not immediately accessible upon the

^{*} Corresponding author at: Secrétariat des Urgences Adultes, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux 33000, France.

patient's admission. Arterial puncture is also a source of pain and complications [5-8].

Validation of a noninvasive tool could allow us to improve triage time and patient orientation upon admission. In particular, the ratio of peripheral arterial oxygen saturation to the inspired fraction of oxygen (SpO₂/FiO₂) has been proposed by several authors [9-12]. However, diagnostic performance of this index has not yet been evaluated.

1.3. Goals of this investigation

This study evaluated the performance of the SpO₂/FiO₂ ratio for predicting mild (PaO₂/FiO₂ superior to 400 mmHg) or moderate (PaO₂/FiO₂ inferior to 300 mmHg) hypoxemia, and evaluated the performance of this index among patients admitted during the COVID-19 outbreak, with subgroup analyses distinguishing SARS-CoV-2 positive and negative patients.

2. Methods

2.1. Study design and setting

We performed a retrospective observational cohort study to assess the predictive value of SpO_2/FiO_2 for the PaO_2/FiO_2 ratio among adult patients admitted to our ED from February to April 2020. The study center is an academic-level hospital in France and was the regional referral center for COVID-19 patient management during the pandemic.

We followed the Standards for Reporting of Diagnostic Accuracy criteria for diagnostic performance studies [13]. Our study is in accordance with the current regulations in France relative to protection of personal health and privacy data.

2.2. Data collection

We extracted the following from our computer data system (*DxCare*® software, France): data on demographics, medical history, vital signs at admission and time of arterial blood sampling, presence of oxygen therapy, oxygen flow rate (QO2) at arterial puncture, SARS-CoV-2 virological status, final diagnosis, and blood gas results for each arterial sample during ED admission including PaO₂, arterial hemoglobin saturation (SaO₂), and arterial carbon dioxide partial pressure (PaCO₂). Data collection was planned subsequent to admission of the study period and from whom an arterial blood sampling was performed

were reviewed. The diagnosis of COVID-19 infection was retained in our analyses in cases of a positive PCR and/or typical lesions in chest CT scans (when performed).

FiO2 was estimated from the interface used for oxygen delivery (nasal cannulas, single mask, high-concentration mask, non-invasive ventilation) and oxygen flow rate. For nasal-cannula or single-mask oxygen therapy, FiO2 was estimated from the data presented by Wettstein et al [14] using the formula FiO2 = 4. QO2 + 21%. For the high-concentration mask, FiO2 was estimated at 80%. For non-invasive ventilation, the FiO2 value selected was the one set on the ventilator.

Pulsed oxygen saturation was measured using pulse oximeters (Space Labs Healthcare Qube™, USA). The quality of the measurement was controlled by a nurse with simultaneous visualization of the plethysmography curve. Arterial blood gas analyses were performed immediately after sampling with a Werfen Instrumentation Laboratory GEM Premier 5000[™] (Spain).

2.3. Choice of PaO₂/FiO₂ thresholds

The PaO₂/FiO₂ thresholds chosen to plot ROC curves were 300 and 400 mmHg, respectively. The 300 mmHg threshold corresponds to the definition of both severe COVID-19 [15], and ARDS [16]. The 400 mmHg threshold corresponds to changes in hematosis relative to observed normal [17] and is used for early detection of hypoxemia, such as in the SOFA score [18].

2.4. Inclusion and exclusion criteria

This study included patients over 18 years of age who were admitted to our ED and underwent vital sign recording and arterial blood gas sampling less than 1 h apart. Exclusion criteria were the absence of recording of one of the parameters studied, a suspicion of blood gas analyses using venous samples (defined as SaO₂ inferior to 75% with SpO₂ superior to 95%), and the presence of hyperoxygenation (defined as the presence of oxygen therapy despite SaO₂ superior to 99%). We did not exclude samples collected for extra-respiratory indications.

2.5. Statistical analyses

Calculation of the SpO₂/FiO₂ values and determination of the mean areas under the receiver-operating characteristic (ROC) curves of SpO₂/FiO₂ for PaO₂/FiO₂ threshold values of 300 and 400 mmHg, as




Fig. 1. Flowchart of the study.

well as their confidence intervals, were performed using R software version 3.6.3 (pROC package) [19]. Agreement between SpO₂/FiO₂ and PaO₂/FiO₂ ratios was assessed using Spearman's rank correlation coefficient. Subgroup analysis of COVID-19 positive and negative patients was conducted using Delong's test of equivalence on ROC curves of both subgroups for PaO₂/FiO₂ threshold values of 300 and 400 mmHg. SpO₂/FiO₂ thresholds were determined using the weighted closest topleft method (pROC package).

3. Results

3.1. Characteristics of the study subjects

During the study period, 564 patients underwent one or more blood gas analyses for a total of 765 blood samples. After application of the exclusion criteria, 430 blood samples from 395 patients were included in

Table 1

Characteristics of study subjects

Patients characteristics N = 395 Age, median (IQR) 60 (44–78) Gender, male, N (%) 91 (23.0%) Comorbidities: 91 (23.0%) acridiac, N (%) 91 (23.0%) heart failure, N (%) 40 (10.1%) coronary artery disease, N (%) 30 (7.5%) other cardiac disease, N (%) 33 (8.4%) pulmonary, N (%) 48 (12.2%) asthma, N (%) 48 (12.2%) chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) other, N (%) 10 (2.53%) chronic kidney disease, N (%) 20 (7.2%) other, N (%) 30 (8.4%) Chronic kidney disease, N (%) 20 (2.2.8%) chronic kidney disease, N (%) 20 (2.2.8%) chronic kidney disease, N (%) 20 (2.2.8%) copitive, N (%) 20 (2.2.8%) negative, N (%) 20 (2.2.8%) copitive, N (%) 20 (2.2.8%) copitive, N (%) 20 (2.2.8%) CoPD exacerbation, N (%)	characteristics of study subjects	
Gender, male, $N(%)$ 193 (48.9%) Comorbidities: 91 (23.0%) cardiac, $N(%)$ 91 (23.0%) heart failure, $N(%)$ 71 (18.0%) atrial fibrillation, $N(%)$ 40 (10.1%) coronary artery disease, $N(%)$ 33 (8.4%) pulmonary, $N(%)$ 118 (29.9%) asthma, $N(%)$ 48 (12.2%) Chronic obstructive pulmonary disease(COPD), $N(%)$ 51 (12.9%) lung carcinosis, $N(%)$ 10 (2.53%) restrictive lung disease, $N(%)$ 10 (2.53%) other, $N(%)$ 10 (2.53%) restrictive lung disease, $N(%)$ 20 (7.34%) COVID-19 status 90 (22.8%) positive, $N(%)$ 30 (22.8%) negative, $N(%)$ 90 (22.8%) negative, $N(%)$ 291 (73.7%) SARS-CoV-2, $N(%)$ 291 (73.7%) SARS-CoV-2, $N(%)$ 291 (53.2%) cordingenic pulmonary odema, $N(%)$ 21 (5.32%) respiratory acute viral syndrome (undetermined), $N(%)$ 21 (5.32%) cardiagenic pulmonary odeema, $N(%)$ 21 (5.32%) respiratory disease, $N(%)$ 20 (5.06%) Extra-respiratory disease, $N(%)$	Patients characteristics	N = 395
Comorbidities: 91 (23.0%) heart failure, N (%) 71 (18.0%) atrial fibrillation, N (%) 40 (10.1%) coronary artery disease, N (%) 30 (7.6%) other cardiac disease, N (%) 33 (8.4%) pulmonary, N (%) 118 (29.9%) asthma, N (%) 48 (12.2%) chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) other, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) cOVID-19 status 90 (22.8%) cOVD exacerbation, N (%) 21 (5.32%) Acute disease, N (%) 20 (7.37%) SAR2-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 21 (5.32%) Pneumonia, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18	Age, median (IQR)	60 (44-78)
cardiac, N (%) 91 (23.0%) heart failure, N (%) 71 (18.0%) atrial fibrillation, N (%) 40 (10.1%) coronary artery disease, N (%) 33 (8.4%) pulmonary, N (%) 33 (8.4%) pulmonary, N (%) 118 (29.9%) asthma, N (%) 48 (12.2%) Chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) Acute kidney failure, N (%) 33 (8.4%) Chronic kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 84 (77-101) Systolic blood pressure, median (IQR) 77 (68-87) SpO2, median (IQR)	Gender, male, N (%)	193 (48.9%)
heart failure, N (%) 71 (18.0%) atrial fibrillation, N (%) 40 (10.1%) coronary artery disease, N (%) 33 (8.4%) pulmonary, N (%) 118 (29.9%) asthma, N (%) 48 (12.2%) Chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) Acute kidney failure, N (%) 33 (8.4%) Chronic kidney disease, N (%) 10 (2.53%) Acute kidney failure, N (%) 33 (8.4%) COVID-19 status 29 (7.34%) positive, N (%) 90 (22.8%) negative, N (%) 90 (22.8%) cOPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) Acute asthma, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 77 (68-87)	Comorbidities:	
atrial fibrillation, $N(X)$ 40 (10.1%)coronary artery disease, $N(X)$ 30 (7.6%)other cardiac disease, $N(X)$ 33 (8.4%)pulmonary, $N(X)$ 118 (29.9%)asthma, $N(X)$ 48 (12.2%)Chronic obstructive pulmonary disease(COPD), $N(X)$ 51 (12.9%)lung carcinosis, $N(X)$ 10 (2.53%)restrictive lung disease, $N(X)$ 10 (2.53%)other, $N(X)$ 10 (2.53%)Acute kidney failure, $N(X)$ 29 (7.34%)COVID-19 status90 (22.8%)negative, $N(X)$ 90 (22.8%)negative, $N(X)$ 90 (22.8%)negative, $N(X)$ 90 (22.8%)COVID-19 status90 (22.8%)polimonary disease, $N(X)$ 291 (73.7%)SARS-COV-2, $N(X)$ 90 (22.8%)COPD exacerbation, $N(X)$ 21 (5.32%)Acute asthma, $N(X)$ 18 (4.56%)Pneumonia, $N(X)$ 49 (12.4%)Cardiogenic pulmonary oedema, $N(X)$ 20 (5.06%)Extra-respiratory acute viral syndrome (undetermined), $N(X)$ 72 (18.3%)others, $N(X)$ 20 (5.06%)Extra-respiratory disease, $N(X)$ 104 (26.3%)Vital signs:118Heart rate, median (IQR)77 (68-87)SpO2, median (IQR)71 (68-87)SpO2, median (IQR)71 (36-6-37.5)Blood gas analysisN = 430Sample from COVID-19 patient, $N(X)$ 24 (12.4%)FiO2 (X), median (IQR)77.9 (96.4-98.9)PaC2 (mmHg), median (IQR)74.4 (7.41-7.47)PaC2/FIO2 > 400, $N(X)$ 134 (31.2%)PaO2/FIO2 <	cardiac, N (%)	91 (23.0%)
coronary artery disease, N (%) 30 (7.6%) other cardiac disease, N (%) 33 (8.4%) pulmonary, N (%) 118 (29.9%) astma, N (%) 48 (12.2%) Chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) other, N (%) 33 (8.4%) Chronic kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 291 (73.7%) SARS-COV-2, N (%) 291 (73.7%) SARS-COV-2, N (%) 20 (5.32%) COPD exacerbation, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 129 (115-144) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 77 (36.6-37.5) Blod gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) </td <td>heart failure, N (%)</td> <td>71 (18.0%)</td>	heart failure, N (%)	71 (18.0%)
other cardiac disease, N (%) 33 (8.4%) pulmonary, N (%) 118 (29.9%) asthma, N (%) 48 (12.2%) Chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) other, N (%) 33 (8.4%) Chronic kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 305 (77.2%) Diagnosis at discharge 90 (22.8%) pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 77 (68-87) SpO2, median (IQR) 77 (68-87) SpO2, median (IQR)	atrial fibrillation, N (%)	40 (10.1%)
pulmonary, N (%)118 (29.9%)asthma, N (%)48 (12.2%)Chronic obstructive pulmonary disease (COPD), N (%)51 (12.9%)lung carcinosis, N (%)10 (2.53%)restrictive lung disease, N (%)10 (2.53%)other, N (%)10 (2.53%)Acute kidney failure, N (%)33 (8.4%)Chronic kidney disease, N (%)29 (7.34%)COVID-19 status90 (22.8%)positive, N (%)90 (22.8%)negative, N (%)90 (22.8%)Diagnosis at discharge90 (22.8%)pulmonary disease, N (%)291 (73.7%)SARS-CoV-2, N (%)90 (22.8%)COPD exacerbation, N (%)21 (5.32%)Acute asthma, N (%)49 (12.4%)Cardiogenic pulmonary oedema, N (%)21 (5.32%)respiratory acute viral syndrome (undetermined), N (%)72 (18.3%)others, N (%)20 (5.06%)Extra-respiratory disease, N (%)104 (26.3%)Vital signs:129 (115-1144)Diastolic blood pressure, median (IQR)27 (168-87)SpO2, median (IQR)77 (68-87)SpO2, median (IQR)22 (18-28)Temperature (°C), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)83.3 (71.3-97.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)7.44 (7.41-7.47)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 > 400, N (%)134 (31.2%)SaO2/FiO2 = 400, N (%)134 (31.2%) <t< td=""><td>coronary artery disease, N (%)</td><td>30 (7.6%)</td></t<>	coronary artery disease, N (%)	30 (7.6%)
asthma, N (%)48 (12.2%)Chronic obstructive pulmonary disease(COPD), N (%)51 (12.9%)lung carcinosis, N (%)10 (2.53%)restrictive lung disease, N (%)10 (2.53%)other, N (%)10 (2.53%)Acute kidney failure, N (%)23 (8.4%)Chronic kidney disease, N (%)29 (7.34%)COVID-19 status90 (22.8%)positive, N (%)90 (22.8%)negative, N (%)90 (22.8%)Diagnosis at discharge90 (02.8%)pulmonary disease, N (%)291 (73.7%)SARS-CoV-2, N (%)90 (22.8%)COPD exacerbation, N (%)21 (5.32%)Acute asthma, N (%)18 (4.56%)Pneumonia, N (%)21 (5.32%)respiratory acute viral syndrome (undetermined), N (%)72 (18.3%)others, N (%)20 (5.06%)Extra-respiratory disease, N (%)104 (26.3%)Vital signs:104 (26.3%)Heart rate, median (IQR)88 (77-101)Systolic blood pressure, median (IQR)129 (115-144)Diastolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)97 (96-98.5)Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)83.3 (71.3-97.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)83.3 (71.3-97.5)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 > 400, N (%)134 (31.2%	other cardiac disease, N (%)	33 (8.4%)
Chronic obstructive pulmonary disease(COPD), N (%) 51 (12.9%) lung carcinosis, N (%) 10 (2.53%) restrictive lung disease, N (%) 10 (2.53%) Acute kidney failure, N (%) 33 (8.4%) Chronic kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 90 (22.8%) positive, N (%) 90 (22.8%) positive, N (%) 90 (22.8%) coVID-19 status 90 (22.8%) pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (15.32%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 129 (115-144) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 77 (68-87) SpO2, median (IQR) 27 (18-6-37.5)<	pulmonary, N (%)	118 (29.9%)
lung carcinosis, N (%)10 (2.53%)restrictive lung disease, N (%)16 (4.05%)other, N (%)10 (2.53%)Acute kidney failure, N (%)33 (8.4%)Chronic kidney disease, N (%)29 (7.34%)COVID-19 status90 (22.8%)positive, N (%)90 (22.8%)negative, N (%)90 (22.8%)Diagnosis at discharge90 (22.8%)pulmonary disease, N (%)291 (73.7%)SARS-CoV-2, N (%)90 (22.8%)COPD exacerbation, N (%)21 (5.32%)Acute asthma, N (%)18 (4.56%)Pneumonia, N (%)49 (12.4%)Cardiogenic pulmonary oedema, N (%)21 (5.32%)respiratory acute viral syndrome (undetermined), N (%)72 (18.3%)others, N (%)104 (26.3%)Vital signs:104 (26.3%)Heart rate, median (IQR)88 (77-101)Systolic blood pressure, median (IQR)97 (95-99)Ventilatory rate, median (IQR)21 (15-144)Diastolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)33 (71.3-97.5)SaO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)36.3 (21.3-40.5)pH, median (IQR)36.3 (23.3-40.5)pH, median (IQR)36.4 (3.26.5-450)PaO2/FiO2 (mmHg), median (IQR)36.4 (3.26.5-450)PaO2/FiO2 (mmHg), median (IQR)36.4 (3.26.5-450)PaO2/FiO2 (mmHg), median (IQR)36.4 (3.26.5-450)PaO2/FiO2 = 400, N (%)134 (31.2%)PaO2/FiO2 = 300, N (%)	asthma, N (%)	48 (12.2%)
restrictive lung disease, N (%) 16 (4.05%) other, N (%) 10 (2.53%) Acute kidney failure, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 90 (22.8%) positive, N (%) 90 (22.8%) pagnosis at discharge 90 (22.8%) pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 77 (68-87) SpO2, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 21 (21-29) PaO2 (moldan (IQR) 21 (21-29) PaO2 (moldan (IQR) 21 (21-29) PaO2 (moldan (IQR) 36.0 (32.3-40.5)	Chronic obstructive pulmonary disease(COPD), N (%)	51 (12.9%)
other, N (%) 10 (2.53%) Acute kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 305 (77.2%) Diagnosis at discharge 90 (02.28%) pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 74 (7.41-7.47) PaO2 (mmHg), med	lung carcinosis, N (%)	10 (2.53%)
other, N (%) 10 (2.53%) Acute kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) positive, N (%) 90 (22.8%) negative, N (%) 305 (77.2%) Diagnosis at discharge 90 (02.28%) pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 74 (7.41-7.47) PaO2 (mmHg), med	restrictive lung disease, N (%)	16 (4.05%)
Chronic kidney disease, N (%) 29 (7.34%) COVID-19 status 90 (22.8%) negative, N (%) 305 (77.2%) Diagnosis at discharge pulmonary disease, N (%) 291 (73.7%) SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 21 (5.32%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 77 (68-87) SpO2, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 37 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 36.0 (32.3-40.5) PAO2 (mmHg), median (IQR) 36.0 (32.3-40.5) PAO2 (mmHg), median (10 (2.53%)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Acute kidney failure, N (%)	33 (8.4%)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Chronic kidney disease, N (%)	29 (7.34%)
negative, N (%) 305 (77.2%) Diagnosis at discharge $291 (73.7\%)$ pulmonary disease, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 48 (77-101) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 97.9 (96.4-98.9) PaC02 (mmHg), median (IQR) 7.44 (7.41-7.47) PaO2 (moldan (IQR) 6.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 (mmHg), median (IQR) 134 (31.2%)		
Diagnosis at discharge pulmonary disease, N (%)291 (73.7%) SARS-CoV-2, N (%)90 (22.8%) O (22.8%)COPD exacerbation, N (%)21 (5.32%) Acute asthma, N (%)18 (4.56%) Pneumonia, N (%)18 (4.56%) Pneumonia, N (%)Cardiogenic pulmonary oedema, N (%)21 (5.32%) respiratory acute viral syndrome (undetermined), N (%)72 (18.3%) others, N (%)cardiogenic pulmonary oedema, N (%)20 (5.06%) Extra-respiratory disease, N (%)104 (26.3%)Vital signs:104 (26.3%)Heart rate, median (IQR)129 (115-144)Diastolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)22 (18-28)Temperature (°C), median (IQR)21 (21-29)PaO2 (mode gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)97.9 (96.4-98.9)PaC02 (mmHg), median (IQR)36.0 (32.3-40.5)Pheo2/FiO2 (mmHg), median (IQR)36.43 (269.5-450)PaO2/FiO2 > 400, N (%)124 (38.1%)PaO2/FiO2 < 300-400, N (%)	positive, N (%)	90 (22.8%)
pulmonary disease, N (%)291 (73.7%)SARS-CoV-2, N (%)90 (22.8%)COPD exacerbation, N (%)21 (5.32%)Acute asthma, N (%)18 (4.56%)Pneumonia, N (%)49 (12.4%)Cardiogenic pulmonary oedema, N (%)21 (5.32%)respiratory acute viral syndrome (undetermined), N (%)72 (18.3%)others, N (%)20 (5.06%)Extra-respiratory disease, N (%)104 (26.3%)Vital signs:104 (26.3%)Heart rate, median (IQR)88 (77-101)Systolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)22 (18-28)Temperature (°C), median (IQR)37 (36.6-37.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)97.9 (96-98.9)PaC02 (mmHg), median (IQR)36.0 (32.3-40.5)PAO2 (mmHg), median (IQR)36.4.3 (269.5-450)PaO2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 = 300, N (%)134 (31.2%)SaO2/FiO2, median (IQR)452.4	negative, N (%)	305 (77.2%)
SARS-CoV-2, N (%) 90 (22.8%) COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 104 (26.3%) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 37 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 36.0 (32.3-40.5) PH 97.9 (96.4-98.9) PaCO2 (mmHg), median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 > 400, N (%) 164 (38.1%) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2, median (IQR) 134 (31.2%) SaO2/Fi	Diagnosis at discharge	
COPD exacerbation, N (%) 21 (5.32%) Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 129 (115–144) Heart rate, median (IQR) 88 (77–101) Systolic blood pressure, median (IQR) 77 (68–87) SpO2, median (IQR) 97 (95–99) Ventilatory rate, median (IQR) 22 (18–28) Temperature (°C), median (IQR) 37 (36.6–37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (27–29) PaO2 (mmHg), median (IQR) 36.0 (32.3–40.5) pH, median (IQR) 97.9 (96.4–98.9) PaCO2 (mmHg), median (IQR) 36.43 (269.5–450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 < 300-400, N (%)	pulmonary disease, N (%)	291 (73.7%)
Acute asthma, N (%) 18 (4.56%) Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 129 (115–144) Heart rate, median (IQR) 88 (77–101) Systolic blood pressure, median (IQR) 97 (95–99) Ventilatory rate, median (IQR) 97 (95–99) Ventilatory rate, median (IQR) 37 (36.6–37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21–29) PaO2 (mmHg), median (IQR) 97.9 (96.4–98.9) PACO2 (mmHg), median (IQR) 36.0 (32.3–40.5) pH, median (IQR) 7.44 (7.41–7.47) PaO2/FiO2 (mmHg), median (IQR) 36.43 (269.5–450) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5–450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 < 300–400, N (%)	SARS-CoV-2, N (%)	90 (22.8%)
Pneumonia, N (%) 49 (12.4%) Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 104 (26.3%) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 97 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 83.3 (71.3-97.5) SaO2 (%), median (IQR) 97.9 (96.4-98.9) PACO2 (mmHg), median (IQR) 36.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2 (FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 < 300-400, N (%)	COPD exacerbation, N (%)	21 (5.32%)
Cardiogenic pulmonary oedema, N (%) 21 (5.32%) respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: Heart rate, median (IQR) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 22 (18-28) Temperature (°C), median (IQR) 37 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 36.0 (32.3-40.5) PdaC2 (mmHg), median (IQR) 36.0 (32.3-40.5) PdaC2 (mmHg), median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 > 400, N (%) 134 (31.2%) PaO2/FiO2, median (IQR) 461.2 Sa02/FiO2, median (IQR) 461.2 Sa02/FiO2, median (IQR) 452	Acute asthma, N (%)	18 (4.56%)
respiratory acute viral syndrome (undetermined), N (%) 72 (18.3%) others, N (%) 20 (5.06%) Extra-respiratory disease, N (%) 104 (26.3%) Vital signs: 104 (26.3%) Heart rate, median (IQR) 88 (77-101) Systolic blood pressure, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 22 (18-28) Temperature (°C), median (IQR) 37 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 97.9 (96.4-98.9) PaC02 (mmHg), median (IQR) 97.9 (96.4-98.9) PaC02 (mmHg), median (IQR) 36.0 (32.3-40.5) PH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 < 300-400, N (%)	Pneumonia, N (%)	49 (12.4%)
others, N (%)20 (5.06%)Extra-respiratory disease, N (%)104 (26.3%)Vital signs:104 (26.3%)Heart rate, median (IQR)88 (77-101)Systolic blood pressure, median (IQR)129 (115-144)Diastolic blood pressure, median (IQR)97 (95-99)Ventilatory rate, median (IQR)97 (95-99)Ventilatory rate, median (IQR)37 (366-37.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)97.9 (964-98.9)PaC02 (mmHg), median (IQR)97.9 (964-98.9)PaC02 (mmHg), median (IQR)36.0 (32.3-40.5)Pheo2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2, median (IQR)461.2SaO2/FiO2, median (IQR)452.4	Cardiogenic pulmonary oedema, N (%)	21 (5.32%)
Extra-respiratory disease, N (%)104 (26.3%)Vital signs: $Heart rate, median (IQR)$ 88 (77-101)Systolic blood pressure, median (IQR)129 (115-144)Diastolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)22 (18-28)Temperature (°C), median (IQR)37 (36.6-37.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)83.3 (71.3-97.5)SaO2 (%), median (IQR)97.9 (96.4-98.9)PaCO2 (mmHg), median (IQR)36.0 (32.3-40.5)pH, median (IQR)7.44 (7.41-7.47)PaO2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 > 400, N (%)132 (30.7%)PaO2/FiO2 < 300, N (%)	respiratory acute viral syndrome (undetermined), N (%)	72 (18.3%)
Vital signs: 88 (77-101) Heart rate, median (IQR) 129 (115-144) Diastolic blood pressure, median (IQR) 77 (68-87) SpO2, median (IQR) 97 (95-99) Ventilatory rate, median (IQR) 22 (18-28) Temperature (°C), median (IQR) 37 (36.6-37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21-29) PaO2 (mmHg), median (IQR) 83.3 (71.3-97.5) SaO2 (%), median (IQR) 97.9 (96.4-98.9) PaCO2 (mmHg), median (IQR) 36.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 132 (30.7%) PaO2/FiO2 < 300-400, N (%)	others, N (%)	20 (5.06%)
Heart rate, median (IQR)88 (77-101)Systolic blood pressure, median (IQR)129 (115-144)Diastolic blood pressure, median (IQR)77 (68-87)SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)22 (18-28)Temperature (°C), median (IQR)37 (36.6-37.5)Blood gas analysisN = 430Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)97.9 (96.4-98.9)PaCO2 (mmHg), median (IQR)97.9 (96.4-98.9)PaCO2 (mmHg), median (IQR)36.0 (32.3-40.5)pH, median (IQR)7.44 (7.41-7.47)PaO2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 < 300-400, N (%)	Extra-respiratory disease, N (%)	104 (26.3%)
Systolic blood pressure, median (IQR) 129 (115–144) Diastolic blood pressure, median (IQR) 77 (68–87) SpO2, median (IQR) 97 (95–99) Ventilatory rate, median (IQR) 22 (18–28) Temperature (°C), median (IQR) 37 (36.6–37.5) Blood gas analysis N = 430 Sample from COVID-19 patient, N (%) 94 (21.9%) FiO2 (%), median (IQR) 21 (21–29) PaO2 (mmHg), median (IQR) 83.3 (71.3–97.5) SaO2 (%), median (IQR) 97.9 (96.4–98.9) PaCO2 (mmHg), median (IQR) 36.0 (32.3–40.5) PH, median (IQR) 7.44 (7.41–7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5–450) PaO2/FiO2 > 400, N (%) 164 (38.1%) PaO2/FiO2 < 300–400, N (%)	Vital signs:	
$\begin{array}{llllllllllllllllllllllllllllllllllll$		88 (77-101)
SpO2, median (IQR)97 (95-99)Ventilatory rate, median (IQR)22 (18-28)Temperature (°C), median (IQR)37 (36.6-37.5)Blood gas analysis $N = 430$ Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)83.3 (71.3-97.5)SaO2 (%), median (IQR)97.9 (96.4-98.9)PaCO2 (mmHg), median (IQR)36.0 (32.3-40.5)pH, median (IQR)7.44 (7.41-7.47)PaO2/FiO2 (mmHg), median (IQR)364.3 (269.5-450)PaO2/FiO2 300-400, N (%)164 (38.1%)PaO2/FiO2 300-400, N (%)132 (30.7%)PaO2/FiO2, median (IQR)461.2SaO2/FiO2, median (IQR)452.4	Systolic blood pressure, median (IQR)	129 (115–144)
Ventilatory rate, median (IQR)22 (18–28)Temperature (°C), median (IQR)37 (36.6–37.5)Blood gas analysis $N = 430$ Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21–29)PaO2 (mmHg), median (IQR)83.3 (71.3–97.5)SaO2 (2%), median (IQR)97.9 (96.4–98.9)PaCO2 (mmHg), median (IQR)36.0 (32.3–40.5)pH, median (IQR)7.44 (7.41–7.47)PaO2/FiO2 (mmHg), median (IQR)364.3 (269.5–450)PaO2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 < 300–400, N (%)	Diastolic blood pressure, median (IQR)	77 (68-87)
Temperature (°C), median (IQR) $37 (36.6-37.5)$ Blood gas analysis $N = 430$ Sample from COVID-19 patient, N (%) $94 (21.9\%)$ FiO2 (%), median (IQR) $21 (21-29)$ PaO2 (mmHg), median (IQR) $83.3 (71.3-97.5)$ SaO2 (%), median (IQR) $97.9 (96.4-98.9)$ PaCO2 (mmHg), median (IQR) $36.0 (32.3-40.5)$ pH, median (IQR) $7.44 (7.41-7.47)$ PaO2/FiO2 (mmHg), median (IQR) $364.3 (269.5-450)$ PaO2/FiO2 > 400, N (%) $164 (38.1\%)$ PaO2/FiO2 < 300-400, N (%)	SpO2, median (IQR)	97 (95-99)
Blood gas analysis $N = 430$ Sample from COVID-19 patient, N (%)94 (21.9%)FiO2 (%), median (IQR)21 (21-29)PaO2 (mmHg), median (IQR)83.3 (71.3-97.5)SaO2 (%), median (IQR)97.9 (96.4-98.9)PaCO2 (mmHg), median (IQR)36.0 (32.3-40.5)pH, median (IQR)7.44 (7.41-7.47)PaO2/FiO2 (mmHg), median (IQR)364.3 (269.5-450)PaO2/FiO2 > 400, N (%)164 (38.1%)PaO2/FiO2 < 300-400, N (%)		22 (18-28)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Temperature (°C), median (IQR)	37 (36.6-37.5)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Blood gas analysis	N = 430
PaO2 (mmHg), median (IQR) 83.3 (71.3-97.5) SaO2 (%), median (IQR) 97.9 (96.4-98.9) PaCO2 (mmHg), median (IQR) 36.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 164 (38.1%) PaO2/FiO2 300-400, N (%) 132 (30.7%) PaO2/FiO2 < 300, N (%)	Sample from COVID-19 patient, N (%)	94 (21.9%)
SaO2 (%), median (IQR) 97.9 (96.4-98.9) PaCO2 (mmHg), median (IQR) 36.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 300-400, N (%) 164 (38.1%) PaO2/FiO2 300-400, N (%) 132 (30.7%) PaO2/FiO2 < 300, N (%)	FiO2 (%), median (IQR)	21 (21-29)
PaCO2 (mmHg), median (IQR) 36.0 (32.3-40.5) pH, median (IQR) 7.44 (7.41-7.47) PaO2/FiO2 (mmHg), median (IQR) 364.3 (269.5-450) PaO2/FiO2 > 400, N (%) 164 (38.1%) PaO2/FiO2 300-400, N (%) 132 (30.7%) PaO2/FiO2 < 300, N (%)	PaO2 (mmHg), median (IQR)	83.3 (71.3-97.5)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	SaO2 (%), median (IQR)	97.9 (96.4–98.9)
$\label{eq:response} \begin{array}{llllllllllllllllllllllllllllllllllll$	PaCO2 (mmHg), median (IQR)	36.0 (32.3-40.5)
$\begin{array}{ll} PaO2/FiO2 > 400, N~(\%) & 164~(38.1\%) \\ PaO2/FiO2~300-400, N~(\%) & 132~(30.7\%) \\ PaO2/FiO2 < 300, N~(\%) & 134~(31.2\%) \\ SaO2/FiO2, median~(IQR) & 461.2 \\ & (339.0-470.5) \\ SpO2/FiO2, median~(IQR) & 452.4 \\ \end{array}$	pH, median (IQR)	7.44 (7.41-7.47)
Pa02/Fi02 300-400, N (%) 132 (30.7%) Pa02/Fi02 < 300, N (%)	PaO2/FiO2 (mmHg), median (IQR)	364.3 (269.5-450)
Pa02/Fi02 < 300, N (%)	PaO2/FiO2 > 400, N (%)	164 (38.1%)
SaO2/FiO2, median (IQR) 461.2 (339.0-470.5) (339.0-470.5) SpO2/FiO2, median (IQR) 452.4	PaO2/FiO2 300-400, N (%)	132 (30.7%)
(339.0-470.5) SpO2/FiO2, median (IQR) 452.4		, ,
SpO2/FiO2, median (IQR) 452.4	SaO2/FiO2, median (IQR)	461.2
(337.9-466.7)	SpO2/FiO2, median (IQR)	
		(337.9-466.7)

statistical analyses. Fig. 1 shows the flow chart of the study. The characteristics of the patients and blood samples are presented in Table 1.

3.2. Main results

Spearman's rank correlation between SpO₂/FiO₂ and PaO₂/FiO₂ ratios was 0.799 (CI 95% 0.747–0.842). The ROC curves of the SpO₂/FiO₂ ratio among overall (N = 430), COVID-19 positive (N = 94) and negative (N = 336) subgroups for PaO₂/FiO₂ threshold values of 300 and 400 mmHg are shown in Fig. 2. Delong's test for comparison of ROC curves showed no significant difference between the subgroups for PaO2/FiO2 threshold values of 300 mmHg (D = 1.46, *p* = 0.15) and 400 mmHg (D = 0.68, *p* = 0.50).

The AUCs of ROC curves of overall patients were 0.918 (CI 95% 0.885–0.950) for a PaO2/FiO2 threshold of 300 mmHg and 0.901 (CI 95% 0.872–0.930) for a PaO2/FiO2 threshold of 400 mmHg. Analysis of SpO2/FiO2 performance shows a specificity of SpO2/FiO2 superior to 470 of 0.98 (CI95% 0.96–0.99) with a positive predictive value (PPV) of 0.89 (CI95% 0.75–0.96) for PaO2/FiO2 superior to 400 mmHg. Specificity of SpO2/FiO2 inferior to 350 was 0.95 (CI95% 0.91–0.97) with PPV of 0.88 (CI95% 0.84–0.91) for PaO2/FiO2 inferior to 300 mmHg.

4. Discussion

4.1. Synthesis of relevant results

The SpO₂/FiO₂ ratio in our cohort showed a good association with the PaO₂/FiO₂ ratio. In this series, the use of thresholds of 370 and 450 showed satisfactory diagnostic performances for the positive diagnosis of PaO₂/FiO₂ < 300 mmHg and exclusion of a PaO₂/FiO₂ < 400 mmHg. Performance was not significantly different between COVID-19 positive and negative patients.

Our results suggest that SpO2/FiO2 can be used for the estimation of the degree of hypoxemia on admission to the emergency room, allowing the patient's severity to be assessed prior to confirmation of viral status. Without other signs of respiratory distress (including increased work of breathing and/or altered mental status), SpO_2/FiO_2 superior to 450 could be used as a decision threshold for outpatient management, whereas SpO_2/FiO_2 inferior to 370 could require referral to intensive care units. An SpO_2/FiO_2 between 370 and 450 would require further clinical evaluation and possibly arterial blood gas.

4.2. Relationship to previous results

Our results support data published by Lu et al. [20], who found that a significant association between SpO_2/FiO_2 decreases and increases mortality risk. Similarly, results recently published by Hamlovich et al. [21] showed the prognostic value of SpO_2 and FiO_2 in the initial assessment of the severity of COVID-19 patients. In this context, our results support the possibility of using SpO_2/FiO_2 by admission nurses as a tool for triage and early referral of patients admitted for respiratory symptoms.

4.3. Limitations

This study had several limitations. First, its retrospective design is subject to several biases. In particular, the SARS-CoV-2 virological status is based on the presence of a positive PCR and/or CT scan with typical lesions. The number of false positives is likely to be small; thus, we can assume the existence of many false negatives, particularly in patients who have not had a CT scan or if the CT scan was performed too early, which may be negative during the first few days of symptom progression [22].

The population sample collected over this period cannot be considered representative of a standard sample of patients consulted in an ED. Significantly more patients were admitted for respiratory symptoms during the period. In addition, relatively fewer patients were admitted

American Journal of Emergency Medicine 44 (2021) 116-120




Fig. 2. ROC curves of the Sp02/FiO2 ratio for PaO2/FiO2 threshold values of 300 mmHg (blue) and 400 mmHg (green), for overall (left), COVID-19 negative (center) and positive (right) patients.

for other indications as they may have avoided consultations to reduce their exposure to viral contamination.

Blood gas measurements performed for acute respiratory distress were included, as well as for non-respiratory reasons, considering that validation of SpO_2/FiO_2 in non-hypoxemic patients was necessary to exclude significant hypoxemia at triage. Hyperoxygenated patients were excluded from the analyses, in whom the SpO_2/FiO_2 ratio is artificially lowered by a nonlinear evolution of SpO_2 (limited between 99% and 100%) compared to FiO_2 . This choice limits the use of these results for triage, where pre-hospital treatment may have imposed significant oxygen therapy during transport to the hospital center, leading to hyperoxygenation at admission to the ED. The use of SpO_2/FiO_2 then requires a prior decrease in FiO_2 to obtain an SpO_2 of less than 99%.

Finally, this study evaluated the performance of SpO₂/FiO₂ based on its association with a biological criterion. An evaluation based on a clinical criterion would be more relevant and would allow for a better assessment of the interest of this index in practice. In particular, previous studies [23,24] have shown that the relationship between PaO₂ and FiO₂ is not linear. Thus, the PaO₂/FiO₂ ratio depends on the FiO₂, and its evolution in cases of FiO₂ variation depends on the fraction of shunt and the ventilation/perfusion mismatch. As such, a perfect correlation between SaO₂/FiO₂ and PaO₂/FiO₂ would mean that SaO₂/FiO₂ has the same drawbacks.

5. Conclusion

In summary, our results suggest that SpO₂/FiO₂ could be a useful index for triage upon admission of patients consulting for acute respiratory symptoms, particularly with suspicion of COVID-19, and would identify patients who could be managed on an outpatient basis and patients requiring admission to the intensive care unit. The use of this index nevertheless requires oxygen titration to ensure the absence of hyperoxygenation, and does not take into account the other dimensions of the respiratory assessment (including work of breathing and mental status).

Future studies are required for a prospective evaluation of the diagnostic performance of SpO_2/FiO_2 among COVID-19 patients, as well as in the acute respiratory tract. In particular, the use of a clinical criterion such as mortality, length of hospitalization, the need for admission to intensive or conventional care could allow us to more accurately assess the contribution of SpO_2/FiO_2 in emergency medicine triage, providing options in addition to PaO_2/FiO_2 .

Declaration of Competing Interest

The authors have no conflict of interest to declare.

References

- Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;385(25): 1451–2460.
- [2] ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.
- [3] Offner PJ, Moore EE. Lung injury severity scoring in the era of lung protective mechanical ventilation: the PaO2/FIO2 ratio. J Trauma. 2003;55(2):285–9.
- [4] Esteve F, Lopez-Delgado JC, Javierre C, Skaltsa K, Carrio ML, Rodríguez-Castro D, et al. Evaluation of the PaO2/FiO2 ratio after cardiac surgery as a predictor of outcome during hospital stay. BMC Anesthesiol. 2014;14:83.
- [5] Crawford A. An audit of the patient's experience of arterial blood gas testing. Br J Nurs. 2004;13(9):529–32.
- [6] Mortensen JD. Clinical sequelae from arterial needle puncture, cannulation, and incision. Circulation. 1967;35(6):1118–23.
- [7] Giner J, Casan P, Belda J, González M, Miralda RM, Sanchis J. Pain during arterial puncture. Chest. 1996;110(6):1443–5.
- [8] Halpern AA, Mochizuki R, Long 3rd CE. Compartment syndrome of the forearm following radial-artery puncture in a patient treated with anticoagulants. JBJS. 1978;60 (8):1136–7.
- [9] Sanz F, Dean N, Dickerson J, Jones B, Knox D, Fernández-Fabrellas E, et al. Accuracy of PaO2 /FiO2 calculated from SpO2 for severity assessment in ED patients with pneumonia. Respirol Carlton Vic. 2015;20(5):813–8.
- [10] Pandharipande PP, Shintani AK, Hagerman HE, St Jacques PJ, Rice TW, Sanders NW, et al. Derivation and validation of SpO2/FiO2 ratio to impute for PaO2/FiO2 ratio in the respiratory component of the sequential organ failure assessment (SOFA) score. Crit Care Med. 2009;37(4):1317–21.
- [11] Katsuya H, Sakanashi Y. Simple and noninvasive indicator of pulmonary gas exchange impairment using pulse oximetry. J Clin Monit. 1989;5(2):82–6.
- [12] Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, et al. Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute respiratory distress syndrome. Chest. 2016;150(2):307–13.
- [13] Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351.
- [14] Wettstein RB, Shelledy DC, Peters JI. Delivered oxygen concentrations using lowflow and high-flow nasal cannulas. Respir Care. 2005;50(5):604–9.
- [15] China National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment7th ed., ; 2020.
- [16] Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012 Jun 20;307(23):2526–33.
- [17] Trulock EP. Arterial blood gases. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: The history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990.
- [18] Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707–10.

- [19] Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J, et al. pROC: an opensource package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(77).
- [20] Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, et al. Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19. Respir Res. 2020;21(1):194.
- [21] Haimovich A, Ravindra NG, Stoytchev S, Young HP, PerryWilson F, van Dijk D, et al. Development and validation of the quick COVID-19 severity index (qCSI): a prognostic tool for early clinical decompensation. Ann Emerg Med. 2020;76(4):442–53.
- [22] Wang Y-C, Luo H, Liu S, Huang S, Zhou Z, Yu Q, et al. Dynamic evolution of COVID-19 on chest computed tomography: experience from Jiangsu Province of China. Eur Radiol. 2020;30(11):6194–203.
- [23] Aboab J, Louis B, Jonson B, Brochard L, Relation between PaO2/FIO2 ratio and FIO2: a mathematical description. Intensive Care Med. 2006;32(10):1494–7.
 [24] Karbing DS, Kjærgaard S, Smith BW, Espersen K, Allerød C, Andreassen S, et al. Var-
- [24] Karbing DS, Kjærgaard S, Smith BW, Espersen K, Allerød C, Andreassen S, et al. Variation in the PaO2/FiO2 ratio with FiO2: mathematical and experimental description, and clinical relevance. Crit Care. 2007;11(6):R118.